Signature Diagnostics AG to Present Company's Blood-Based Colorectal Cancer Screening Strategy at the 18th UEGW Congress in Barcelona
Published: Oct 27, 2010
POTSDAM, GERMANY--(Marketwire - October 26, 2010) - Signature Diagnostics AG announced today that the company was selected to present its newest blood-based products for colorectal cancer (CRC) screening -- Detector C and Detector C/Plus -- at the 18th United European Gastrointestinal Week (UEGW) Congress in Barcelona on October 22-26, 2010. The paper, "Early Detection of Colorectal Cancer Based on RNA Measurements in Blood," will be presented by the company's CEO, André Rosenthal, Ph.D, at the session "Colorectal Cancer Screening: New Strategies" on Wednesday, October 26, 2010 (Hall 14, 8:30-10:30am).
Both Detector C and Detector C/Plus are extremely accurate and safe with a validated sensitivity of 90 percent and a validated specificity of up to 92.5 percent. Both tests should be applicable to individuals who dislike colonoscopy due to bowel cleaning and its invasiveness, dislike stool-based tests, or are above 70-years-old and may have conditions that increase the risks of colonoscopy and side effects.
"The use of Detector C and Detector C/Plus as primary screening tools not only increases sensitivity and specificity of blood-based CRC screening, but would result in significantly fewer unnecessary colonoscopies in countries where screening colonoscopy is reimbursed," said André Rosenthal. "The test's low false positive rate of 7.5 percent is close to that of colonoscopy and ensures that endoscopy resources will not be exhausted by large-scale use of this blood-based test."
About Signature Diagnostics AG
Signature Diagnostics AG is a molecular diagnostics company based in Potsdam, Germany, focusing on the development and commercialization of novel molecular oncology diagnostic products for early detection (screening) and prognosis of cancer. The company has completed development of its first two diagnostic products for colorectal cancer screening ("Detector C/C+") and prognosis ("Predictor C"), which will be launched in early 2011 in its own ISO 15189 certified service laboratory. Using its state-of-the-art technologies in tissue and blood sample collection, molecular pathology, Xenopatient™ platform, genome-wide profiling, data mining, and biostatistics, the company collaborates with clinical, pharmaceutical, and diagnostic partners. Signature Diagnostics sponsors and conducts large prospective, multicenter clinical trials with more than 25 primary care hospitals and several dozen colonoscopy centers in Germany to discover and validate biomarkers in oncology.
Hermannswerder 20 A Potsdam Germany
Press release (PDF): http://hugin.info/143237/R/1455579/395446.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
For questions, please contact:
Prof. Dr. André Rosenthal, CEO
14473 Potsdam, Germany